Acarbose - CAS 56180-94-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acarbose
Catalog Number:
56180-94-0
Synonyms:
BAY g 5421
CAS Number:
56180-94-0
Description:
Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.
Molecular Weight:
645.6
Molecular Formula:
C25H43NO18
COA:
Inquire
MSDS:
Inquire
Targets:
Others
Chemical Structure
CAS 56180-94-0 Acarbose

Related Products


CP-664511
(CAS: 379692-00-9)

CP-664511 is a potent compound that is a alpha4beta1/vascular cell adhesion molecule-1 (VCAM-1) inhibitor which has therapeutic potential in treating allergic a...

CAS 1709-70-2 Antioxidant 330

Antioxidant 330
(CAS: 1709-70-2)

Antioxidant 330 is an antioxidant that could be used in sorts of areas or materials as an stablizer.

Ponatinib hydrochloride
(CAS: 1114544-31-8)

Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leuke...

CAS 69-25-0 Eledoisin

Eledoisin
(CAS: 69-25-0)

Eledoisin is an undecapeptide of mollusk origin and it belongs to the tachykinin family of neuropeptides. It was first isolated from the posterior salivary glan...

CAS 34097-16-0 Clocortolone Pivalate

Clocortolone Pivalate
(CAS: 34097-16-0)

Clocortolone Pivalate is a Corticosteroid Hormone Receptor Agonist. It is used for the treatment of dermatitis and is considered a medium-strength corticosteroi...

CAS 78-28-4 Emylcamate

Emylcamate
(CAS: 78-28-4)

Emylcamateis an anxiolytic and muscle relaxant. It can be used for the treatment of anxiety and tension.

CAS 120938-72-9 LY 243670

LY 243670
(CAS: 120938-72-9)

LY 243670 is a bio-active molecular, but detailed information were not published yet.

CAS 594839-88-0 Tafamidis

Tafamidis
(CAS: 594839-88-0)

Tafamidis is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. It is a drug for the amelioration of transthyretin-relat...

CAS 130-95-0 Quinine

Quinine
(CAS: 130-95-0)

Quinine is a primary alkaloid of various species of Cinchona. Because of its relatively constant and well-known fluorescence quantum yield, quinine is also used...

CAS 84687-42-3 Astragaloside III

Astragaloside III
(CAS: 84687-42-3)

Astragaloside III is a saponin found in the root of Astragalus membranaceus (Fisch.) Bunge, which is known as huáng qí in Traditional Chinese Medicine. It has c...

PLX-7683
(CAS: 1652573-86-8)

PLX-7683, a pyrrolopyridine derivative, has been found to be a paradox breaker that was studied to exhibit more durable efficacy and better safety than some for...

NCT-501
(CAS: 1802088-50-1)

NCT-501 is a potent and selective inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1) with IC50 of 40 nM.

CAS 314728-85-3 Sunifiram

Sunifiram
(CAS: 314728-85-3)

unifiram (DM-235) is a piperazine derived research chemical which has nootropic effects in animal studies with significantly higher potency than piracetam.

CAS 35899-54-8 5'-Isobutylthio-5'-deoxyadenosine

5'-Isobutylthio-5'-deoxyadenosine
(CAS: 35899-54-8)

5'-Isobutylthio-5'-deoxyadenosine acts as a selectively spermine with IC50=8 uM.

CAS 6747-15-5 D,L-3-Indolylglycine

D,L-3-Indolylglycine
(CAS: 6747-15-5)

D, L-3-Indolylglycine, similar to Tryptophan, is an unnatural amino acid.

CAS 141625-93-6 Dronedarone  HCl

Dronedarone HCl
(CAS: 141625-93-6)

Dronedarone HCl is a therapy for the treatment of patients with paroxysmal and persistent atrial fibrillation or atrial flutter.

CAS 2276-90-6 Iothalamic Acid

Iothalamic Acid
(CAS: 2276-90-6)

Iothalamic Acid, similar to those of diatrizoic acid, as conventional ionic contrast medioum Iothalamic Acid displayed the same level of nephrotoxicity against ...

CAS 481-46-9 Ginkgetin

Ginkgetin
(CAS: 481-46-9)

Ginkgetin is a natural biflavonoid isolated from leaves of Ginkgo biloba L. According to reports, it has anti-inflammatory and anti-cancer effects.

CAS 74285-86-2 triptophenolide

triptophenolide
(CAS: 74285-86-2)

triptophenolide is isolated from ethyl acetate extracts of the roots of Tripterygium wilfordii Hook. f. In vitro, it can remarkably inhibit the delayed type hyp...

CAS 2199-58-8 PYR-9588

PYR-9588
(CAS: 2199-58-8)

PYR-9588 is an intermediate used in the chemical synthesis of a series of anaplastic lymphoma kinase (ALK) inhibitors.

Reference Reading


1.Characterization of two coleopteran α-amylases and molecular insights into their differential inhibition by synthetic α-amylase inhibitor, acarbose.
Channale SM1, Bhide AJ1, Yadav Y1, Kashyap G1, Pawar PK2, Maheshwari VL3, Ramasamy S4, Giri AP5. Insect Biochem Mol Biol. 2016 Apr 27;74:1-11. doi: 10.1016/j.ibmb.2016.04.009. [Epub ahead of print]
Post-harvest insect infestation of stored grains makes them unfit for human consumption and leads to severe economic loss. Here, we report functional and structural characterization of two coleopteran α-amylases viz. Callosobruchus chinensis α-amylase (CcAmy) and Tribolium castaneum α-amylase (TcAmy) along with their interactions with proteinaceous and non-proteinaceous α-amylase inhibitors. Secondary structural alignment of CcAmy and TcAmy with other coleopteran α-amylases revealed conserved motifs, active sites, di-sulfide bonds and two point mutations at spatially conserved substrate or inhibitor-binding sites. Homology modeling and molecular docking showed structural differences between these two enzymes. Both the enzymes had similar optimum pH values but differed in their optimum temperature. Overall, pattern of enzyme stabilities were similar under various temperature and pH conditions. Further, CcAmy and TcAmy differed in their substrate affinity and catalytic efficiency towards starch and amylopectin.
2.Reply to 'Long-term use of acarbose and CV event: confusing finding from mega data bank'.
Chang CH1,2,3, Chang YC3,4,5, Lin JW3,6, Chuang LM1,2,3. Diabet Med. 2016 May 2. doi: 10.1111/dme.13145. [Epub ahead of print]
We appreciate the comments on the discrepancy among the studies raised by Wu et al. However, the study designs and comparators for the acarbose treatment group in the three studies are obviously different. The first study by Chen et al. compared the risk of developing cardiovascular disease (CVD) among patients with Type 2 diabetes receiving various durations and doses of acarbose and those never receiving acarbose [1]. This study did not distinguish between acarbose monotherapy and combination therapy or between first-line acarbose therapy and second-line acarbose therapy. This article is protected by copyright. All rights reserved.
3.Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose.
Singla RK, Singh R, Dubey AK1. Curr Top Med Chem. 2016 Apr 14. [Epub ahead of print]
Acarbose, a well known and efficacious α-amylase and α-glucosidase inhibitor, is a post-prandial acting antidiabetic drug. DNS-based α-amylase inhibitory assays showed that use of acarbose at concentrations above 125 µg/ml resulted in release of reducing sugar in the reaction, an unexpected observation. Objective of the present study was to design experimental strategies to address this unusual finding. Acarbose was found to be susceptible to thermo-lysis. Further, besides being an inhibitor, it could also be hydrolyzed by porcine pancreatic α-amylase, but had weaker affinity for α-amylase compared to starch. GRIP docking was done for the mechanistic analysis of the active site in the enzyme for substrate, inhibitor and, inhibitor's metabolite (K2). Interaction between acarbose and α-amylase involved significant hydrogen binding compared to that of starch, producing a stronger enzyme-inhibitor complex. Further, docking analysis led us to predict the site on α-amylase where the inhibitor (acarbose) bound more tightly, which possibly affected the binding and hydrolysis of starch exerting its effective anti-diabetic function.
4.Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obese.
Sun W1, Zeng C2, Liao L1, Chen J1, Wang Y3. Curr Med Res Opin. 2016 Apr 7:1-34. [Epub ahead of print]
OBJECTIVE: To compare the efficacy of acarbose and metformin in overweight and/or obese patients with newly diagnosed type 2 diabetes mellitus (T2DM).